Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634320 | 0.95 | MAOB (0.59) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| SCHEMBL934147 | 0.91 | HDAC1 (0.57) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| Hydrochloric Acid SCHEMBL30882461 | 0.89 | HDAC1 (0.55) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| SCHEMBL25138775 | 0.89 | HDAC1 (0.59) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| Trifluoroacetic Acid SCHEMBL4788988 | 0.89 | MAOB (0.53) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| SCHEMBL934424 | 0.87 | HDAC1 (0.58) | TAAR1FFAR1PDPK1MAOBHDAC1 | |
| Cadaverine Tartrate SCHEMBL3634787 | 0.85 | MAOB (0.49) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| SCHEMBL7332151 | 0.84 | FFAR1 (0.57) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| SCHEMBL11801516 | 0.82 | FFAR1 (0.55) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 | |
| SCHEMBL117230 | 0.82 | FFAR1 (0.73) | TAAR1FFAR1PDPK1PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428754-A | Two ring Quinazol derivatives | 豪夫迈·罗氏有限公司 | 2017-12-01 | — | — | CN | claimed |
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-7763618-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2010-07-27 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| JP-2007500716-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-12-28 | — | — | US | claimed |
| EP-1708992-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | claimed |
| EP-1067113-B1 | Process for the preparation of phenethylamines and intermediates therefor | LANXESS DEUTSCHLAND GMBH (DE) | 2005-07-20 | — | — | EP | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| EP-3632892-B1 | METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2024-07-31 | — | — | EP | disclosed |
| US-4957533-A | THIOAMIDES, AMIDINES | ELI LILLY AND COMPANY (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0314422-A2 | N-phenylalkylbenzamide fungicides | DOWELANCO (US) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | PRMT9, SNRPD3, PRDX5 | TAAR1 3878/4885FFAR1 685/4885PDPK1 1634/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | TAAR1 2558/4885FFAR1 27/4885PDPK1 1679/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | TAAR1 4300/4885FFAR1 3097/4885PDPK1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.